-
公开(公告)号：US08778304B2
公开(公告)日：2014-07-15
申请号：US13034320
申请日：2011-02-24
申请人： Martin G. Pomper , Haofan Wang , Tomas R. Guilarte
发明人： Martin G. Pomper , Haofan Wang , Tomas R. Guilarte
CPC分类号： A61K51/0459 , C07B59/002 , C07D487/04 , G01N33/60 , G01N2333/705 , G01N2800/7095
摘要： Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.
摘要翻译： 描述了转运蛋白（TSPO）靶向化合物。 还描述了制备化合物的方法和化合物用于成像的用途。
-
公开(公告)号：US20110212025A1
公开(公告)日：2011-09-01
申请号：US13034320
申请日：2011-02-24
申请人： Martin G. Pomper , Haofan Wang , Tomas R. Guilarte
发明人： Martin G. Pomper , Haofan Wang , Tomas R. Guilarte
IPC分类号： A61K51/04 , C07D487/04 , C12Q1/02 , A61K49/00
CPC分类号： A61K51/0459 , C07B59/002 , C07D487/04 , G01N33/60 , G01N2333/705 , G01N2800/7095
摘要： Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.
摘要翻译： 描述了转运蛋白（TSPO）靶向化合物。 还描述了制备化合物的方法和化合物用于成像的用途。
-
3.发明授权Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents 有权标记的前列腺特异性膜抗原（PSMA）的抑制剂，生物学评价和用作成像剂公开(公告)号：US09044468B2
公开(公告)日：2015-06-02
申请号：US12666441
申请日：2008-06-26
IPC分类号： A61K51/04 , A61K31/513 , A61K31/4402 , A61K31/145 , A61K31/195 , A61K31/395 , A61K38/06 , C07D213/38 , C07D215/12 , C07D257/00 , G01N33/574
CPC分类号： A61K51/0472 , A61K31/145 , A61K31/195 , A61K31/395 , A61K31/4402 , A61K38/06 , A61K51/0402 , C07D213/38 , C07D215/12 , C07D257/00 , C07D257/02 , C07F13/00 , C12Q1/37 , G01N33/57434 , G01N33/60 , G01N2500/04 , A61K2300/00
摘要： The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
摘要翻译： 前列腺特异性膜抗原（PSMA）越来越被认为是癌症成像和治疗的可行靶标。 通过将已知的Tc / Re螯合剂连接到具有或不具有可变长度连接体部分的氨基官能化PSMA抑制剂中来制备各种99mTc / Re标记的化合物。 离体生物分布和体内成像证明了与工程化PSMA + PC3 PIP肿瘤的特异性结合程度。
-
公开(公告)号：US08273326B2
公开(公告)日：2012-09-25
申请号：US11629607
申请日：2005-06-20
申请人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
发明人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
CPC分类号： A61K51/1241 , A61K51/0491 , A61K51/1231
摘要： The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
摘要翻译： 本发明提供了一种用于通过向受试者施用适合于与感染生物体中存在的胸腺嘧啶激酶结合的成像的化合物并且获得受试者的图像来确定受试者的感染的存在和位置的方法， 化合物，其中化合物的定位表明受试者具有感染。
-
5.发明申请PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER 有权前列腺特异性膜抗原（PSMA）用于治疗前列腺癌的靶向纳米颗粒公开(公告)号：US20110200677A1
公开(公告)日：2011-08-18
申请号：US12744982
申请日：2008-11-26
IPC分类号： A61K9/14 , A61K48/00 , A61K38/02 , A61K31/70 , A61K38/14 , A61P35/00 , A61P35/04 , A61P35/02 , A61P29/00 , A61P17/06 , A61P17/02 , A61P17/00 , A61P37/08 , A61P25/00 , A61P11/06 , A61P11/00 , A61P9/00 , A61P9/10 , A61P7/02 , A61P9/12 , A61P1/00 , A61P1/04 , A61P31/04 , A61P31/12 , A61P31/18 , A61P31/22 , A61P31/16 , A61P37/06 , A61P19/10 , A61P25/28 , A61P25/16 , A61P25/02 , B82Y5/00
CPC分类号： A61K9/51 , C07C275/16 , Y10S977/773 , Y10S977/906 , Y10S977/911
摘要： The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
摘要翻译： 本发明提供了用几乎所有实体瘤表达的前列腺特异性膜抗原（PSMA）的基于尿素的小分子肽模拟抑制剂装饰的纳米颗粒组合物。 该策略利用功能化纳米颗粒的结合PSMA的亲合力和纳米颗粒在肿瘤中保留更长时间的能力，这是由于通过EPR增加到肿瘤间质中的渗漏以及由于欠发育而导致差的清除 肿瘤内不存在淋巴管。
-
公开(公告)号：US20110176998A1
公开(公告)日：2011-07-21
申请号：US12903842
申请日：2010-10-13
IPC分类号： A61K51/00 , C07F5/02 , C07C229/66 , C07D261/18 , C07D235/32 , C07H19/09 , C07D209/46 , C07F5/00 , C07F9/00 , C12Q1/70 , C12N5/09 , A61P29/00 , A61P31/12 , A61P35/00 , A61P31/04
CPC分类号： A61K51/0491 , A61K31/00 , A61K31/192 , A61K31/403 , A61K31/4168 , A61K31/42 , A61K31/7068 , A61K33/22 , A61K45/06 , A61K2300/00 , Y02A50/402 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479
摘要： The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
摘要翻译： 本发明的特征在于用于检测，选择与病毒感染相关的瘤形成的治疗方法，监测和治疗的组合物和方法。
-
7.发明授权Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer 有权前列腺特异性膜抗原（PSMA）靶向纳米颗粒治疗前列腺癌公开(公告)号：US09422234B2
公开(公告)日：2016-08-23
申请号：US12744982
申请日：2008-11-26
IPC分类号： A61K9/14 , A61K9/51 , C07C275/16
CPC分类号： A61K9/51 , C07C275/16 , Y10S977/773 , Y10S977/906 , Y10S977/911
摘要： The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
摘要翻译： 本发明提供了用几乎所有实体瘤表达的前列腺特异性膜抗原（PSMA）的基于尿素的小分子肽模拟抑制剂装饰的纳米颗粒组合物。 该策略利用功能化纳米颗粒的结合PSMA的亲合力和纳米颗粒在肿瘤中保留更长时间的能力，这是由于通过EPR增加到肿瘤间质中的渗漏以及由于欠发育而导致差的清除 肿瘤内不存在淋巴管。
-
公开(公告)号：US08691186B2
公开(公告)日：2014-04-08
申请号：US13596632
申请日：2012-08-28
申请人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
发明人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
CPC分类号： A61K51/1241 , A61K51/0491 , A61K51/1231
摘要： The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
摘要翻译： 本发明提供了一种用于通过向受试者施用适合于与感染生物体中存在的胸腺嘧啶激酶结合的成像的化合物并且获得受试者的图像来确定受试者的感染的存在和位置的方法， 化合物，其中化合物的定位表明受试者具有感染。
-
公开(公告)号：US20130064767A1
公开(公告)日：2013-03-14
申请号：US13596632
申请日：2012-08-28
申请人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
发明人： Martin G. Pomper , Chetan Bettegowda , Catherine Foss , Shibin Zhou , Kenneth Kinzler , Bert Vogelstein
CPC分类号： A61K51/1241 , A61K51/0491 , A61K51/1231
摘要： The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
摘要翻译： 本发明提供了一种用于通过向受试者施用适合于与感染生物体中存在的胸腺嘧啶激酶结合的成像的化合物并且获得受试者的图像来确定受试者的感染的存在和位置的方法， 化合物，其中化合物的定位表明受试者具有感染。
-
10.发明申请Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor 审中-公开成像剂和α7-烟碱型胆碱能受体成像方法公开(公告)号：US20100034741A1
公开(公告)日：2010-02-11
申请号：US12321951
申请日：2009-01-26
申请人： Martin G. Pomper , John L. Musachio , Hong Fan , Robert F. Dannals , Catherine Foss , Eifion Phillips , John Gordon , Dennis McCarthy , Richard Keith , Mark Smith , Richard Heys , Peter N. Dorff
发明人： Martin G. Pomper , John L. Musachio , Hong Fan , Robert F. Dannals , Catherine Foss , Eifion Phillips , John Gordon , Dennis McCarthy , Richard Keith , Mark Smith , Richard Heys , Peter N. Dorff
IPC分类号： C07D453/02 , C07D453/00 , A61K51/04 , G01N33/53
CPC分类号： C07D491/22 , A61K51/0448 , C07B2200/05 , C07D453/02
摘要： The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the α7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express α7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.
摘要翻译： 本发明涉及放射性标记的化合物，特别是1-氮杂双环[2.2.2]辛烷化合物（即奎宁环化合物），其被一个或多个放射性同位素标记并适用于成像或治疗处理组织，器官或肿瘤，其表达 α7-烟碱性胆碱能受体。 在另一个实施方案中，本发明涉及使用本发明的放射性标记化合物，特别是表达本发明化合物具有亲和力的α7-烟碱型胆碱能受体的组织，器官或肿瘤来成像组织，器官或肿瘤的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.025 秒)
